Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
116.34
+3.69 (3.28%)
At close: Jul 22, 2025, 4:00 PM
116.33
-0.01 (-0.01%)
After-hours: Jul 22, 2025, 4:25 PM EDT
Jazz Pharmaceuticals Employees
Jazz Pharmaceuticals had 2,800 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
2,800
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$1,451,717
Profits / Employee
$172,213
Market Cap
7.04B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
JAZZ News
- 11 hours ago - Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025 - PRNewsWire
- 12 days ago - Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer - PRNewsWire
- 15 days ago - Is JAZZ Stock Undervalued At $110? - Forbes
- 15 days ago - Jazz Pharmaceuticals: I See Big Potential In This Stock As An Investor - Seeking Alpha
- 21 days ago - Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer - PRNewsWire
- 6 weeks ago - Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer - PRNewsWire
- 6 weeks ago - Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025 - PRNewsWire
- 7 weeks ago - Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer - PRNewsWire